Keep In Touch: Communication Maintains Ongoing Purdue/Shionogi Pact
Executive Summary
The private US pain specialist and Japanese pharma have partnered for more than a decade to develop novel pain candidates, but despite perhaps slow progress, the level of collaboration has grown with strong communication.
You may also be interested in...
Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine
Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.